These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28961308)

  • 1. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
    Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
    Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
    J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
    Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
    J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
    Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
    J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe, reversible nelarabine-induced neuropathy and myelopathy.
    Alberti P; Parma M; Pioltelli P; Pogliani EM; Terruzzi E; Stasia A; Doni E; Cecchetti C; Cavaletti G
    J Peripher Nerv Syst; 2016 Sep; 21(3):154-6. PubMed ID: 27117493
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
    Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
    Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
    Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
    Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
    J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
    Hartz B; Löbel U; Hagel C; Escherich G
    Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
    Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
    Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.